Cabometyx 2021 report

Cabometyx 2021 report
Cabometyx 2021 report
Posted in

[sf_modal header=”Sample Report Request” btn_colour=”lightgrey” btn_type=”standard” extraclass=”280-width” btn_size=”small” btn_text=” REQUEST A FREE SAMPLE”]

    Name (required)

    Company (required)

    Email Address (required)

    [/sf_modal]

    [sf_button colour=”lightgrey” link=/reports/ target=”_self” dropshadow=”no” extraclass=”set_t_width”]FIND ANOTHER REPORT[/sf_button]

    Cabometyx 2021 U.S. PROMOTIONAL AUDIT REPORT

    Published July 2022 • 26 Pages

    The 5 Key Questions Addressed by this Report:

    • How many physicians were reached by Cabometyx through reportable promotional activity in 2021 and how does this compare to its peer set in the Renal Cancer and Thyroid Cancer markets?
    • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
    • How does Exelixis’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Nursing, Medical Oncology, Physician Assistant, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
    • How often are physicians receiving paid meals for Cabometyx throughout the year (e.g., monthly, quarterly, annually)?
    • Who were the most frequent meal recipients and top paid speakers for Cabometyx in 2021?

    Data Sources and Methodology:

    • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
    • Over 4,050 paid interactions across 2,090 physicians made on behalf of Cabometyx were carefully examined to support our analysis. In addition, interaction data from 9 peer products (e.g. Bavencio, Fotivda, Inlyta, Keytruda, Lenvima, Mvasi, Opdivo, Tafinlar, and Zirabev ) was leveraged to provide benchmarking and market insights.